Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Ublituximab and Umbralisib in Combination With Targeted Immunotherapy in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT) of CLL

Next Previous
Trial Profile

Phase I Study of Ublituximab and Umbralisib in Combination With Targeted Immunotherapy in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT) of CLL

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cosibelimab (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary) ; Pembrolizumab
  • Indications Chronic lymphocytic leukaemia; Richter's syndrome
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc

Most Recent Events

  • 21 Dec 2021 Status changed from active, no longer recruiting to completed.
  • 20 Sep 2021 Results presented in the TG Therapeutics Media Release.
  • 30 Aug 2021 According to a TG Therapeutics Inc media release, data from this trial will be presented at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually in September 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top